Skip to main content
Elad Sharon, MD, Oncology, Boston, MA

EladSharonMD

Oncology • Boston, MA

Physician

Join to view full profile

Dr. Sharon is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Sharon's full profile

Already have an account?

  • Office

    450 Brookline Ave
    Boston, MA 02215
    Phone+1 617-632-6140
    Fax+1 617-632-2933

Education & Training

  • National Institutes of Health Clinical Center
    National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 2007 - 2011
  • Emory University School of Medicine
    Emory University School of MedicineResidency, Internal Medicine, 2003 - 2006
  • Baylor College of Medicine
    Baylor College of MedicineClass of 2003

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 2008 - 2026
  • DC State Medical License
    DC State Medical License 2012 - 2024
  • GA State Medical License
    GA State Medical License 2006 - 2017
  • MD State Medical License
    MD State Medical License 2012 - 2013
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

Journal Articles

  • Pembrolizumab in Mycosis Fungoides and Sézary Syndrome: Updated Results of the CITN Multicenter Phase 2 Study  
    Michael S Khodadoust, Pierluigi Porcu, Francine Foss, Andrei R Shustov, Satish Shanbhag, Lubomir Sokol, Steven M Horwitz, Elad Sharon, European Journal of Cancer
  • Immuno-Oncology Trial Endpoints: Capturing Clinically Meaningful Activity  
    Elad Sharon, Patrick M Forde, Valsamo Anagnostou, Hao Wang, Franco Verde, Mark Yarchoan, Clinical Cancer Research
  • From Famine to Feast: Developing Early-Phase Combination Immunotherapy Trials Wisely  
    Arta M Monjazeb, Elad Sharon, Clinical Cancer Research

Abstracts/Posters

  • Safety and Efficacy of Brentuximab Vedotin in Combination with AVD in Stage II-IV HIV-Associated Classical Hodgkin Lymphoma: Results of the Phase 2 Study, AMC 085
    Elad Sharon, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Authored Content

  • Pembrolizumab in Mycosis Fungoides and Sézary Syndrome: Updated Results of the CITN Multicenter Phase 2 StudyAugust 2018

Press Mentions

  • Rare Melanoma Very Likely to Respond to Treatment with Pembrolizumab
    Rare Melanoma Very Likely to Respond to Treatment with PembrolizumabMay 5th, 2023
  • Slips, Slides: Winter Injuries Can Be Serious
    Slips, Slides: Winter Injuries Can Be SeriousJanuary 2nd, 2023
  • Drug Approved to Help Young Patients Battle a Rare Cancer
    Drug Approved to Help Young Patients Battle a Rare CancerJanuary 2nd, 2023
  • Join now to see all

Professional Memberships

Dr. Elad Sharon, Dr. Elad Sharon, MD, Dr. E Sharon